Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder
NCT: NCT06953596 · RECRUITING
Brief Summary
Grief is a normal response after the death of a loved one. With time, the grief response decreases and people learn to cope with their loss. However, for some, the response becomes more intense and distressing. This is called prolonged grief disorder (PGD). People with PGD experience emotional pain and a deep longing for their loved one. PGD normally occurs \<10% of people after a loss, but it has become more common since the COVID-19 pandemic (\~30%). If left untreated, PGD leads to poor quality of life and increased risk of death. Treatment options such as medication and therapy are available; however, they can cause negative side effects and take a long time to work. To help individuals with PGD, we need treatments that work well and quickly. Repetitive transcranial magnetic stimulation (rTMS) is a safe, non-invasive treatment that delivers magnetic pulses to brain areas responsible for mood. rTMS has been approved in Canada to treat mood disorders. There is research to show that rTMS is safe and well-tolerated, and that works well in treating Post-Traumatic Stress Disorder (PTSD), a condition with similar symptoms to PGD. To determine whether rTMS is effective for treating PGD, we first need to determine if rTMS as a treatment for PGD is safe and feasible among grieving individuals.
Frequently Asked Questions
What is Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder?
Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder is a clinical trial registered under NCT06953596. Current status: RECRUITING.
What is the status of NCT06953596?
The current status of NCT06953596 (Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder) is: RECRUITING.
When did Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder start?
Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder started on 2025-11-28.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.